Trial Profile
A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Apr 2024
Price :
$35
*
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms MINMON
- 06 Mar 2024 Results assessing HCV re-infection rates among participants with post-treatment HCV RNA >lower limit of quantification (LLoQ), presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024.
- 14 Nov 2023 Results of secondary analysis comparing markers of liver disease before and after treatment in both people with HCV only and HIV & HCV (HIV/HCV) treated using a minimal monitoring approach, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
- 24 Jan 2023 Results assessing correlation of sub-optimal adherence to HCV therapy in a single-arm, multinational, clinical trial published in the Clinical Infectious Diseases